A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in
Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Register AML-BFM 2017 zur Erfassung akuter myeloischer Leukämien bei Kindern und Jugendlichen

Randomisierte Phase III Studie zur intensiven Standardchemotherapie versus intensiver Chemotherapie mit CPX-351 bei erwachsenen Patienten mit einer neu diagnostizierten akuten myeloischen Leukämie und intermediären bzw. ungünstigem genetischen Risiko

Randomized, placebo controlled Phase III Study of Induction and Consolidation chemotherapy with Venetoclax in adult patients with newly diagnosed acute myeloid Leukemia or Myelodyspalstic syndrome with ecxess Blasts-2

Zanubrutinib (Brukinsa®) in patients with Waldenström’s macroglobulinemia (WM), Chronic lymphocytic leukemia (CLL), Marginal zone lymphoma (MZL) and Follicular lymphoma (FL) – a prospective multicenter observational cohort study